Stocks scoring 0–25 beat the S&P 500
39.9% of the time over the next three months, since 2015.
How we measured this →
8
hedge funds
hold it · 2 new, 1 added, 5 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$4.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About TRAVERE THERAPEUTICS INC
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.…
Who's behind the signal
Every informed buyer we can see on TVTX, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
TRAVERE THERAPEUTICS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
2
New positions
1
Increasing
5
Decreasing
0
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to TRAVERE THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TRAVERE THERAPEUTICS INC or any security.